History and Future of HER2-Targeted Therapy for Advanced Gastric Cancer

被引：7

作者：

Ariga, Shin ^{[1
,2
]}

机构：

[1] Hokkaido Univ, Fac Med, Dept Med Oncol, Sapporo 0608638, Japan

[2] Hokkaido Univ, Grad Sch Med, Sapporo 0608638, Japan

来源：

JOURNAL OF CLINICAL MEDICINE | 2023年 / 12卷 / 10期

关键词：

gastric cancer; HER2; targeted therapy; heterogeneity; METASTATIC BREAST-CANCER; ANTIBODY-DRUG CONJUGATE; DERUXTECAN T-DXD; GASTROESOPHAGEAL JUNCTION; TRASTUZUMAB DERUXTECAN; PHASE-II; MONOCLONAL-ANTIBODY; OPEN-LABEL; PLUS CHEMOTHERAPY; HER-2; RECEPTOR;

D O I：

10.3390/jcm12103391

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

Human epidermal growth factor receptor 2 (HER2) is a receptor tyrosine kinase that belongs to the human epidermal growth factor receptor family. It is overexpressed/amplified in approximately 20% of gastric or gastroesophageal junction cancers. HER2 is being developed as a therapeutic target in a variety of cancers, and several agents have been shown to be effective in breast cancer. The development of HER2-targeted therapy for gastric cancer successfully began with trastuzumab. However, while effective in breast cancer, the successive anti-HER2 agents lapatinib, T-DM1, and pertuzumab failed to demonstrate benefits regarding survival in gastric cancer compared with the existing standard therapies. Intrinsic differences lie between gastric and breast cancer in terms of HER2-positive tumor biology, which may make development difficult. Recently, a novel anti-HER2 agent, trastuzumab deruxtecan, was introduced, and the development of HER2-positive gastric cancer agents has been moving to the next stage. This review summarizes the current HER2-targeted therapy for gastric or gastroesophageal cancer in chronological order and describes the promising future of HER2-targeted therapy.

引用

页数：16

共 90 条

[71] Use of chemotherapy plus a monoclonal antibody against HER2 for metastatic breast cancer that overexpresses HER2. [J].

Slamon, DJ ;

Leyland-Jones, B ;

Shak, S ;

Fuchs, H ;

Paton, V ;

Bajamonde, A ;

Fleming, T ;

Eiermann, W ;

Wolter, J ;

Pegram, M ;

Baselga, J ;

Norton, L .

NEW ENGLAND JOURNAL OF MEDICINE, 2001, 344 (11) :783-792

[72] Trastuzumab deruxtecan in patients (pts) with HER2-overexpressing (HER2-OE) metastatic non-small cell lung cancer (NSCLC): Results from the DESTINY-Lung01 trial [J].

Smit, E. F. ;

Felip, E. ;

Uprety, D. ;

Nakagawa, K. ;

Paz-Ares, L. ;

Pacheco, J. ;

Li, B. T. ;

Planchard, D. ;

Baik, C. ;

Goto, Y. ;

Murakami, H. ;

Saltos, A. ;

Saxena, K. ;

Shiga, R. ;

Cheng, Y. ;

Yan, Q. ;

Feng, W. ;

Janne, P. A. .

ANNALS OF ONCOLOGY, 2022, 33 (07) :S994-S995

[73] Gene expression patterns of breast carcinomas distinguish tumor subclasses with clinical implications [J].

Sorlie, T ;

Perou, CM ;

Tibshirani, R ;

Aas, T ;

Geisler, S ;

Johnsen, H ;

Hastie, T ;

Eisen, MB ;

van de Rijn, M ;

Jeffrey, SS ;

Thorsen, T ;

Quist, H ;

Matese, JC ;

Brown, PO ;

Botstein, D ;

Lonning, PE ;

Borresen-Dale, AL .

PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2001, 98 (19) :10869-10874

[74] Paul Ehrlich's magic bullet concept: 100 years of progress [J].

Strebhardt, Klaus ;

Ullrich, Axel .

NATURE REVIEWS CANCER, 2008, 8 (06) :473-480

[75] Primary analysis of MOUNTAINEER: A phase 2 study of tucatinib and trastuzumab for HER2-positive mCRC [J].

Strickler, J. ;

Cercek, A. ;

Siena, S. ;

Andre, T. ;

Ng, K. ;

Van Cutsem, E. ;

Wu, C. ;

Paulson, A. ;

Hubbard, J. ;

Coveler, A. ;

Fountzilas, C. ;

Kardosh, A. ;

Kasi, P. ;

Lenz, H. ;

Ciombor, K. ;

Elez, E. ;

Bajor, D. ;

Stecher, M. ;

Feng, W. ;

Bekaii-Saab, T. .

ANNALS OF ONCOLOGY, 2022, 33 :S375-S376

[76] MOUNTAINEER-02: Phase 2/3 study of tucatinib, trastuzumab, ramucirumab, and paclitaxel in previously treated HER2+gastric or gastroesophageal junction adenocarcinoma: Trial in progress [J].

Strickler, J. ;

Nakamura, Y. ;

Shitara, K. ;

Catenacci, D. ;

Janjigian, Y. ;

Barzi, A. ;

Bekaii-Saab, T. ;

Lenz, H. ;

Lee, J. ;

Van Cutsem, E. ;

Chung, H. ;

Tabernero, J. ;

Yoshino, T. ;

Siena, S. ;

Garrido-Mayor, J. ;

Palanca-Wessels, M. ;

Xie, D. ;

Marshall, J. .

ANNALS OF ONCOLOGY, 2021, 32 :S159-S159

[77] HERIZON-GEA-01: Zanidatamab plus chemo ± tislelizumab for 1L treatment of HER2-positive gastroesophageal adenocarcinoma [J].

Tabernero, Josep ;

Shen, Lin ;

Elimova, Elena ;

Ku, Geoffrey ;

Liu, Tianshu ;

Shitara, Kohei ;

Lin, Xiao ;

Boyken, Lisa ;

Li, Huiyan ;

Grim, Jonathan ;

Ajani, Jaffer .

FUTURE ONCOLOGY, 2022, 18 (29) :3255-3266

[78] Pertuzumab plus trastuzumab and chemotherapy for HER2-positive metastatic gastric or gastro-oesophageal junction cancer (JACOB): final analysis of a double-blind, randomised, placebo-controlled phase 3 study [J].

Tabernero, Josep ;

Hoff, Paulo M. ;

Shen, Lin ;

Ohtsu, Atsushi ;

Shah, Manish A. ;

Cheng, Karen ;

Song, Chunyan ;

Wu, Haiyan ;

Eng-Wong, Jennifer ;

Kim, Katherine ;

Kong, Yoon-Koo .

LANCET ONCOLOGY, 2018, 19 (10) :1372-1384

[79] Phase II Trial of Trastuzumab and Docetaxel in Patients With Human Epidermal Growth Factor Receptor 2-Positive Salivary Duct Carcinoma [J].

Takahashi, Hideaki ;

Tada, Yuichiro ;

Saotome, Takashi ;

Akazawa, Kohei ;

Ojiri, Hiroya ;

Fushimi, Chihiro ;

Masubuchi, Tatsuo ;

Matsuki, Takashi ;

Tani, Kaori ;

Osamura, Robert Y. ;

Hirai, Hideaki ;

Yamada, Shuhei ;

Kawakita, Daisuke ;

Miura, Kouki ;

Kamata, Shin-etsu ;

Nagao, Toshitaka .

JOURNAL OF CLINICAL ONCOLOGY, 2019, 37 (02) :125-+

[80] Trastuzumab emtansine versus taxane use for previously treated HER2-positive locally advanced or metastatic gastric or gastro-oesophageal junction adenocarcinoma (GATSBY): an international randomised, open-label, adaptive, phase 2/3 study [J].

Thuss-Patience, Peter C. ;

Shah, Manish A. ;

Ohtsu, Atsushi ;

Van Cutsem, Eric ;

Ajani, Jaffer A. ;

Castro, Hugo ;

Mansoor, Wasat ;

Chung, Hyun Cheol ;

Bodoky, Gyorgy ;

Shitara, Kohei ;

Phillips, Gail D. Lewis ;

van der Horst, Tina ;

Harle-Yge, Marie-Laurence ;

Althaus, Betsy L. ;

Kang, Yoon-Koo .

LANCET ONCOLOGY, 2017, 18 (05) :640-653

← 1 2 3 4 5 6 7 8 9 →